ClinicalTrials.gg
Not yet recruitingNCT06895512Updated Mar 26, 2025

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

A Phase 3 interventional study of HLX15-IV and Darzalex in Newly Diagnosed Multiple Myeloma, sponsored by Shanghai Henlius Biotech. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
386
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.

Planned enrollment
31st of 406
386 · median 40
Started
2025
with 54 others
Phase 3
66 of 448
24 open now
Primary completion
2027-07
later than 153 of 274 live
Registered
341st of 448
by date

Among the 448 studies in Multiple Myeloma with a site in China, this one is the 31st largest by planned enrollment of the 406 interventional ones that give a count, is one of 55 that started in 2025, is one of 66 in phase 3, reaches primary completion later than 153 of the 274 other live ones, and was the 341st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:

233 more — sign in →

All 238 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Multiple Myeloma with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, parallel-controlled, multicenter, phase III study to compare the efficacy and safety of HLX15-IV in combination with Rd (HLX15-IV-Rd) versus DARZALEX® in combination with Rd (D-Rd) in patients with NDMM who are ineligible for autologous stem cell transplantation (ASCT).

03

Conditions studied

  • Newly Diagnosed Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable to understand and sign the ICF.
  2. Patients aged ≥ 18 years .
  3. Patient must have documented multiple myeloma (MM) satisfying the International Myeloma Working Group (IMWG) diagnostic criteria for MM.
  4. Newly diagnosed, untreated and not considered candidate for stem cell transplantation (ASCT).
  5. Patient must have an performance status score of 0.
  6. Patient must have pretreatment clinical laboratory values.
  7. use by men or women should be consistent with local regulations.
  8. A must have a negative serum pregnancy test at screening within 72 hours prior to randomization.

Exclusion criteria

Exclusion Criteria:

  1. Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  2. Patient has plasma cell leukemia or POEMS syndrome .
  3. Patient has prior or current systemic therapy or for MM before randomization.
  4. Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher.
  5. Patient has a history of (other than MM) within 3 years before randomization .
  6. Patient has clinical signs of meningeal involvement of MM.
  7. Patient has known , persistent asthma, or a history of asthma within the last 2 years.
  8. Patient is known to be seropositive for history of (HIV) or known to have treponema pallidum antibodies (Anti-TP).
  9. Patient is known to have active or C.
  10. Patient has any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results.
  11. Patient has cardiac disease.
  12. Patient has known allergies, , or intolerance to treatment drugs.
  13. Patient has history of drug abuse or substance abuse.
  14. Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes).
  15. Patient had radiation therapy within 14 days of randomization.
  16. Patient had plasmapheresis within 28 days of randomization.
  17. Patient had major surgery within 28 days before randomization.
  18. Patient in clinical trials of any other drug or device within 3 months before randomization.
  19. Patient has any condition could prevent, limit, or confound the protocol-specified assessments.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
386 participants (estimated)

Study arms

  • Experimental
    HLX15-IV-Rd

    HLX15-IV in combination with Lenalidomide-Dexamethasone (Rd)

    Drug: HLX15-IV

  • Active comparator
    DARZALEX-Rd

    DARZALEX in combination with Lenalidomide-Dexamethasone (Rd)

    Drug: Darzalex

Interventions

  • DrugHLX15-IV

    recombinant anti-CD38 human monoclonal antibody injection

  • recombinant anti-CD38 human monoclonal antibody injection

06

What researchers measure

Primary outcomes

  1. IRC-assessed Week 24 rate of very good partial response (VGPR) or better

    the percentage of patients achieving VGPR or CR (including sCR) until Week 24 after the date of randomization.

    Time frame: 24 weeks

Secondary outcomes

  1. Investigator-assessed Week 24 rate of VGPR or better

    the percentage of patients achieving VGPR or CR (including sCR) until Week 24 after the date of randomization

    Time frame: 24 weeks

  2. IRC- and investigator-assessed Week 12, 36 and 48 rate of VGPR or better

    percentage of patients achieving VGPR or CR (including sCR) until Week 12, 36 and 48 after the date of randomization

    Time frame: 12,36,48 weeks

  3. IRC- and investigator-assessed partial response (PR) rate

    the percentage of patients achieving PR at any time point after the date of randomization

    Time frame: 48 weeks

  4. IRC- and investigator-assessed complete response (CR) rate

    the percentage of patients achieving CR at any time point after the date of randomization.

    Time frame: 48 weeks

  5. IRC- and investigator-assessed stringent complete response (sCR) rate

    percentage of patients achieving sCR at any time point after the date of randomization

    Time frame: 48 weeks

  6. IRC- and investigator-assessed complete response (CR) or better rate

    the percentage of patients achieving CR or sCR at any time point after the date of randomization.

    Time frame: 48 weeks

  7. IRC- and investigator-assessed overall response rate

    the percentage of patients who achieve PR or better after the date of randomization.

    Time frame: 48 weeks

  8. IRC- and investigator-assessed time to response (TTR)

    the time from the date of randomization to the date of initial documentation of a response (PR or better) for patient who had achieved a response of PR or better

    Time frame: 48 weeks

  9. IRC- and investigator-assessed duration of response (DOR)

    the date of initial documentation of a response (PR or better) to either progressive disease according the IMWG criteria, or death, whichever occurs first

    Time frame: 48 weeks

  10. IRC- and investigator-assessed progression free survival (PFS)

    the duration from the date of randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first.

    Time frame: 48 weeks

  11. Minimal residual disease (MRD) negative rate

    the percentage of patients who achieve negative MRD at least once during the confirmed complete response (CR) or better according to the IMWG response criteria.

    Time frame: 48 weeks

  12. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Health Status (EORTC-QLQ-C30).

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Health Status (EORTC-QLQ-C30).Minimum and maximum values is according to the items, the score range of item 1-28 is 1-4, the score range of item 29-30 is 1-7. The higher the overall score is, the better the overall quality of life is.

    Time frame: 48 weeks

  13. EuroQoL 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire.

    EuroQoL 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire.The description of health status is divided into five levels.Health Status Index range is -0.59-1.00, VAS range is 0-100.The higher the Health Status Index and VAS score are, the better the health condition is; the lower the dimension description score is, the fewer problems there are.

    Time frame: 48 weeks

  14. Incidence and severity of adverse events (AEs)

    severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version \[v\] 5.0, vital signs and clinical laboratory test results

    Time frame: 52 weeks

  15. Time to reach maximum serum drug concentration at steady state (Tmax, ss)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: 48 weeks

  16. Time to reach maximum serum drug concentration(Tmax)

    Detailed Outcome Measure will be defined in the Statistical Analysis Plan

    Time frame: 48 weeks

  17. Immunogenicity

    Incidence of ADA and/or NAb for HLX15-IV and DARZALEX

    Time frame: 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Jul 2027, 27 months later.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 26, 2025
StartEst.
Apr 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895512
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Apr 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion